Damae Medical Market Research Report
Company Overview
Name and Mission
- Company Name: Damae Medical
- Mission: To revolutionize skin cancer diagnosis by developing non-invasive, high-resolution imaging technologies.
Founding Details
- Founded: September 2014
- Founders: Anaïs BARUT (CEO), David SIRET (CTO), Arnaud DUBOIS (CSO)
Key People
- Anaïs BARUT: CEO
- David SIRET: CTO
- Arnaud DUBOIS: CSO
Headquarters
- Location: Paris, France
- Office Address: 14 rue Sthrau, 75013 Paris, France
Employees
- Number of Employees: Approximately 20 collaborators
Financials
- Revenue: No information is available
Reputation
- Known For: Developing deepLive™ medical device utilizing LC-OCT™ technology for skin analysis and imaging to improve diagnostic accuracy in skin cancer detection.
Products
deepLive™ Medical Device
- Description: A cutting-edge imaging system utilizing LC-OCT™ technology, designed for detailed 3D imaging of skin conditions.
Key Features:
- 3D Imaging Modality: Offers both vertical (histology-like) and horizontal (confocal-like) modes.
- LC-OCT Technology: Provides unique penetration and cellular resolution in 3D, allowing accurate skin condition imaging in situ.
- Non-Invasive: Promotes efficient and reassuring patient management without the need for invasive biopsies.
- Quantitative Analysis: Capable of performing skin surface 3D segmentation, analyzing keratinocytes, and collagen fibers.
Recent Developments
Product Developments
- New Product Launches:
- No new products have been launched beyond deepLive™ within the reported period.
- New Features:
- Integration of a live dermoscopic camera inside the LC-OCT 3D handheld probe (2020).
Corporate Milestones
- 2023: deepLive™ received CE Mark Class IIA under EU MDR 2017/745, marking a significant regulatory achievement.
- 2022: Raised €5M in Series A financing to support European deployment and expand access to the deepLive™ platform.
- 2019: Developed a miniaturized LC-OCT 3D handheld probe and manufactured 10 LC-OCT 3D devices.
Strategic Initiatives
- Partnerships and Funding:
- Successfully closed a €2 million investment round in 2017 with various partners, including Kurma Partners and Idinvest Partners.
- Received €2.4 million in funding from the EU’s Horizon 2020 program to improve skin cancer diagnostics through the OCTAV project.
Key Studies and Publications
- ECOBASO Study (2024): The first French randomized trial to assess deepLive™'s health-economic impact on basal cell carcinoma management.
- Scientific Publications: Over 170 papers published on LC-OCT technology and its applications in dermatology.
Contact Information
- Email: info@damae-medical.com
- Website: www.damae-medical.com
This report reflects the most current and comprehensive data available about Damae Medical, detailing its innovation leadership in the medical imaging industry and commitment to improving skin cancer diagnostics.
